Clinical Trials

A Phase II Study of MLN8237 in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Protocol
12-096
Full Title
Phase II Trial of the Aurora Kinase A Inhibitor MLN8237, in Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma (SWOG #S1108)
Purpose

Some lymphomas, including peripheral T-cell lymphomas (PTCL), have too much of an enzyme called aurora kinase, which makes lymphoma cells grow and divide at a high rate. MLN8237 is an investigational drug that blocks aurora kinase. In early studies, several people with PTCL who took MLN8237 experienced shrinkage or disappearance of their cancers.

The purpose of this study is to assess the safety and effectiveness of MLN8237 in patients with PTCL that has returned or persisted despite prior therapy. MLN8237 is a pill that is taken orally (by mouth).

Investigator
Steven M. Horwitz, MD
Steven M. Horwitz - Physician Profile
Co-Investigators
Andrew D. Zelenetz, MD, PhD
Andrew D. Zelenetz - Physician Profile
Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have PTCL that has returned or persisted despite at least one regimen of prior systemic therapy.
  • At least 3 weeks must have passed since completion of previous chemotherapy or radiation therapy (6 weeks since alemtuzumab or 12 weeks since radio-immunotherapy).
  • Patients must be age 18 or older.

For more information about this study and to inquire about eligibility, please contact Dr. Steven M. Horwitz at 212-639-3045.

Disease(s)
Lymphoma
Lymphoma: Non-Hodgkin's Lymphoma
Locations
ClinicalTrials.gov
Related Diseases